CHRONIC OBSTRUCTIVE PULMONARY DISEASE Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I
暂无分享,去创建一个
M. Decramer | R. Bouillon | T. Troosters | M. Spruit | R. Gosselink | G. Gayan‐Ramirez | A. Kasran | P. Bogaerts | Ahmad Kasran | G. Gayan-Ramirez | T. Troosters | M. Decramer | Marc Decramer | Roger Bouillon | R. Gosselink | A. Kasran | G. Gayan-Ramirez | R. Bouillon | R. Bouillon | M. A. Spruit | R. Bouillon
[1] A. Kenny,et al. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.
[2] Y. Lacasse,et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.
[3] H. Westerblad,et al. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. , 2002, American journal of respiratory and critical care medicine.
[4] M. Decramer,et al. Resistance versus endurance training in patients with COPD and peripheral muscle weakness , 2002, European Respiratory Journal.
[5] G. Verleden,et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? , 2002, European Respiratory Journal.
[6] A. Newman,et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.
[7] G. Schuler,et al. Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.
[8] F. Martinez,et al. Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 2013 .
[9] C. Hart,et al. Myositis in children with meningococcal disease: a role for tumour necrosis factor-alpha and interleukin-8? , 2002, The Journal of infection.
[10] M. Blackman,et al. Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. , 2001, American journal of physiology. Endocrinology and metabolism.
[11] A. Ionescu,et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[12] L. Fried,et al. Association of IGF-I levels with muscle strength and mobility in older women. , 2001, The Journal of clinical endocrinology and metabolism.
[13] E. Wouters,et al. Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations , 2001, Thorax.
[14] F. Graziano,et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. , 2001, Journal of immunological methods.
[15] S. Anker,et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. , 2001, Cytokine.
[16] E. Bozkanat,et al. Skeletal muscle dysfunction in chronic obstructive pulmonary disease , 2001, Respiratory research.
[17] U. Tylén,et al. Neutrophil-associated activation markers in healthy smokers relates to a fall in DL(CO) and to emphysematous changes on high resolution CT. , 2001, Respiratory medicine.
[18] I. Waddell,et al. Proteolysis‐inducing factor regulates hepatic gene expression via the transcription factors NF‐κΒ and STAT3 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] R. Casaburi. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. , 1999, Medicine and science in sports and exercise.
[20] M. Decramer. The respiratory rehabilitation division of the University Hospital Gasthuisberg, Leuven, Belgium , 2001 .
[21] P. Barnes. Potential novel therapies for chronic obstructive pulmonary disease. , 2001, Novartis Foundation symposium.
[22] T. Seemungal,et al. Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.
[23] T. Seemungal,et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[24] E. Wouters,et al. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[25] N. Hopkinson,et al. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. , 2009, American journal of respiratory and critical care medicine.
[26] F. Maltais,et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[27] P. Poole‐Wilson,et al. Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.
[28] R. Schwartz,et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-κB activation in response to tumor necrosis factor α , 1998 .
[29] T. Seemungal,et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.
[30] J. Govan,et al. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. , 1998, Respiratory medicine.
[31] R. Schwartz,et al. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] E. Wouters,et al. Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. , 1997, The European respiratory journal.
[33] W. MacNee,et al. Prognostic significance of plasma D-dimer levels in patients with lung cancer. , 1997, Thorax.
[34] M. Decramer,et al. Muscle weakness is related to utilization of health care resources in COPD patients. , 1997, The European respiratory journal.
[35] E. Wouters,et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.
[36] J. Crowley,et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. , 1996, American journal of respiratory and critical care medicine.
[37] M. Decramer,et al. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.
[38] M. Decramer,et al. Peripheral muscle weakness contributes to exercise limitation in COPD. , 1996, American journal of respiratory and critical care medicine.
[39] K. Fearon,et al. Characterization of a cancer cachectic factor , 1996, Nature.
[40] R. Rogers,et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.
[41] M. Polkey,et al. Quadriceps strength and fatigue assessed by magnetic stimulation of the femoral nerve in man , 1995, Muscle & nerve.
[42] M. Decramer,et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. , 1994, American journal of respiratory and critical care medicine.
[43] N. Agell,et al. Tumour necrosis factor‐α increases the ubiquitinization of rat skeletal muscle proteins , 1993 .
[44] J. Roca,et al. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[45] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[46] J E Cotes,et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[47] N. Agell,et al. Tumour necrosis factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. , 1993, FEBS letters.
[48] N. Anthonisen,et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. , 1987, Annals of internal medicine.
[49] Flick Da,et al. Pharmacokinetics of murine tumor necrosis factor. , 1986 .
[50] D. A. Flick,et al. Pharmacokinetics of murine tumor necrosis factor. , 1986, Journal of immunopharmacology.
[51] V. Mathiowetz,et al. Grip and pinch strength: normative data for adults. , 1985, Archives of physical medicine and rehabilitation.
[52] Müller Ea,et al. Influence of training and of inactivity on muscle strength. , 1970 .
[53] E. Müller,et al. Influence of training and of inactivity on muscle strength. , 1970, Archives of physical medicine and rehabilitation.
[54] L. F. Black,et al. Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .